HALO Stock Discussion (Halozyme Therapeutics, Inc.)

Halozyme prices a larger $1.3 billion convertible financing

Halozyme ($HALO) increased its convertible-note offering to $1.3 billion from $1.05 billion and set a 1.50% coupon. The notes mature in 2033 and initially convert at approximately $139.84 per share, a 27.5% premium to the reference share price. Buyers can purchase another $200 million under an option, while closing is expected on September 22. Expected base net proceeds are approximately $1.275 billion. Planned uses include $162.5 million for capped-call transactions and about $652.5 million to

HALO

@tickerstat1 month ago

Halozyme proposes $1.05 billion convertible refinancing

Halozyme ($HALO) announced plans to sell $1.05 billion of convertible senior notes due in 2033, with an option for initial purchasers to buy a further $150 million. The securities would be senior unsecured obligations paying interest twice a year. The coupon and initial conversion rate were to be determined when the offering is priced. Proceeds are intended partly for capped-call transactions and repurchases of existing convertible notes due in 2027 and 2028, with the remainder available for gen